EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer

Despite the success of treating EGFR mutant lung cancer patients with EGFR tyrosine kinase inhibitors (TKIs), all patients eventually acquire resistance to these therapies. Although various resistance mechanisms have been described, there are currently no FDA-approved therapies that target alternati...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Res
Glavni autori: Amato, Katherine R., Wang, Shan, Tan, Li, Hastings, Andrew K., Song, Wenqiang, Lovly, Christine M., Meador, Catherine B., Ye, Fei, Lu, Pengcheng, Balko, Justin M., Colvin, Daniel C., Cates, Justin M., Pao, William, Gray, Nathanael S., Chen, Jin
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4715957/
https://ncbi.nlm.nih.gov/pubmed/26744526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-0717
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items